Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to learn more about how insulin resistance (inability to process glucose correctly resulting in mildly elevated glucose levels) affects the hormone ghrelin.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: 2,4-thiazolidinedione; Pioglitazone

Criteria

Inclusion Criteria:

• Age 18 to 80, weight stable for at least 3 months

• At lifetime maximal body weight and impaired glucose tolerance (ICT) by the World Health ORganization criteria:

• fasting plasma glucose level of 100- 125mg/dL or

• plasma glucose level between 140 to 149mg/dL following a 75gram oral glucose load

Exclusion Criteria:

• Actively losing weight

• Smokers

• Alcohol consumption > 2 drinks/day

• Prescription drug use

• Recreational drug use

• Type 2 Diabetes

• Conditions that contraindicate treatment with pioglitazone such as CHF, impaired liver or kidney function or known sensitivity to pioglitazone